Tower Research Capital (TRC)’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-7,678
| Closed | -$11K | – | 6561 |
|
|
2023
Q1 | $11K | Buy |
7,678
+741
| +11% | +$998 | ﹤0.01% | 4309 |
|
|
2022
Q4 | $7K | Buy |
6,937
+3,178
| +85% | +$4.28K | ﹤0.01% | 4661 |
|
|
2022
Q3 | $7K | Sell |
3,759
-2,968
| -44% | -$8.61K | ﹤0.01% | 4967 |
|
|
2022
Q2 | $19K | Sell |
6,727
-2,969
| -31% | -$7.33K | ﹤0.01% | 3873 |
|
|
2022
Q1 | $27K | Sell |
9,696
-7,742
| -44% | -$24.4K | ﹤0.01% | 3269 |
|
|
2021
Q4 | $81K | Buy |
17,438
+9,685
| +125% | +$60.5K | ﹤0.01% | 2379 |
|
|
2021
Q3 | $66K | Buy |
7,753
+5,061
| +188% | +$71.5K | ﹤0.01% | 2742 |
|
|
2021
Q2 | $44K | Buy |
2,692
+425
| +19% | +$8.59K | ﹤0.01% | 3137 |
|
|
2021
Q1 | $50K | Buy |
2,267
+1,347
| +146% | +$36.7K | ﹤0.01% | 3132 |
|
|
2020
Q4 | $28K | Sell |
920
-17,608
| -95% | -$445K | ﹤0.01% | 3638 |
|
|
2020
Q3 | $376K | Buy |
18,528
+16,029
| +641% | +$281K | ﹤0.01% | 1987 |
|
|
2020
Q2 | $38K | Buy |
2,499
+544
| +28% | +$6.28K | ﹤0.01% | 3273 |
|
|
2020
Q1 | $15K | Sell |
1,955
-416
| -18% | -$5.09K | ﹤0.01% | 1858 |
|
|
2019
Q4 | $34K | Buy |
2,371
+2,082
| +720% | +$32.2K | ﹤0.01% | 1588 |
|
|
2019
Q3 | $4K | Sell |
289
-1,086
| -79% | -$16.9K | ﹤0.01% | 3484 |
|
|
2019
Q2 | $20K | Buy |
1,375
+294
| +27% | +$4.69K | ﹤0.01% | 2192 |
|
|
2019
Q1 | $19K | Buy |
+1,081
| New | +$19.2K | ﹤0.01% | 2307 |
|
Tower Research Capital (TRC)'s TCRR Position: Q2 2023 in Review
Tower Research Capital (TRC) sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 7,678 shares — an estimated $11K sold.
Tower Research Capital (TRC) first reported a position in TCRR in Q1 2019 and held it in 17 quarters. The position peaked at $376K in Q3 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Tower Research Capital (TRC) reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 7,678 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $11K.
- Tower Research Capital (TRC) first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- Tower Research Capital (TRC)'s TCR2 Therapeutics Inc. Common Stock position peaked at $376K in Q3 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.